Background and Objectives Buprenorphine's high‐binding affinity as a partial µ‐opioid
agonist displaces preexisting full agonists causing precipitated withdrawal, which requires …

Buprenorphine possesses many unique attributes that make it a practical agent for adults
and adolescents with opioid use disorder (OUD) and/or acute or chronic pain. Sublingual …

Study Objective Buprenorphine, a partial μ‐opioid agonist, is an effective treatment for
opioid use disorder that conventionally requires symptoms of withdrawal before initiation to …

Buprenorphine induction for treating opioid use disorder is being implemented in
emergency care. During this era of high-potency synthetic opioid use, novel and divergent …

Objectives: Patients with opioid use disorder (OUD) can initiate buprenorphine without
requiring a withdrawal period through a low-dose (sometimes referred to as “micro …

Background/objectives Micro-induction is a novel buprenorphine induction approach that
seeks to avoid withdrawal and minimize precipitated withdrawal, both barriers to standard …

Background: Converting methadone to buprenorphine/naloxone sublingual (SL) is desirable
for reasons including ease of prescribing, carries to improving function, decreased drug …

Substance use in pregnancy is common; nearly one of five of pregnant individuals have
pastmonth nicotine, alcohol, or illicit substance use, and more than one in 10 meet criteria …

Objective Emergency department (ED)–initiated buprenorphine may prevent overdose.
Microdosing is a novel approach that does not require withdrawal, which can be a barrier to …

Methadone, a full opioid agonist at the mu-, kappa-, and delta-receptor, and buprenorphine,
a partial agonist at the mu receptor, are first-line medications in opioid maintenance …